Gregory Friberg Sells 6,326 Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Gregory Friberg sold 6,326 shares of BioMarin Pharmaceutical stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $60.38, for a total transaction of $381,963.88. Following the transaction, the executive vice president directly owned 37,578 shares of the company’s stock, valued at $2,268,959.64. This represents a 14.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

BioMarin Pharmaceutical Price Performance

Shares of BioMarin Pharmaceutical stock opened at $61.73 on Friday. The company has a current ratio of 5.21, a quick ratio of 3.10 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $11.86 billion, a price-to-earnings ratio of 34.68, a P/E/G ratio of 0.53 and a beta of 0.26. BioMarin Pharmaceutical Inc. has a 1-year low of $50.76 and a 1-year high of $73.51. The firm’s 50-day moving average price is $58.91 and its two-hundred day moving average price is $56.19.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Sanford C. Bernstein published a bullish forecast calling for strong price appreciation for BMRN, which can lift investor expectations ahead of upcoming catalysts. Sanford C. Bernstein Forecast
• Positive Sentiment: Wells Fargo flagged BMRN as an attractive buy ahead of the Transcon‑CNP PDUFA decision, highlighting regulatory upside as a near‑term positive catalyst. Wells Fargo note
• Neutral Sentiment: Coverage pieces analyzing recent share rebound and DCF upside present valuation arguments but offer no clear catalyst; useful for investors modeling scenarios but not an immediate price driver. Valuation/DCF analysis
• Neutral Sentiment: Reported short‑interest data is effectively zero and contains apparent data errors (showing increases of “NaN”); this appears to be a reporting glitch and does not signal a meaningful short squeeze or surge in bearish positioning. (data entries dated Feb 26–27)
• Negative Sentiment: EVP Gregory Friberg sold 6,326 shares for roughly $382k at an average $60.38 on Feb. 26 — an insider sale that can weigh on sentiment, especially given the size relative to his remaining stake. Insider sale filing
• Negative Sentiment: HC Wainwright published a pessimistic forecast for BMRN, which could pressure sentiment among more risk‑sensitive investors. HC Wainwright note
• Negative Sentiment: Oppenheimer lowered its price target to $95, a cut that may temper upside expectations despite other bullish targets — contributes to mixed analyst messaging. Oppenheimer target cut

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BMRN. Tudor Pickering set a $88.00 price objective on BioMarin Pharmaceutical in a research report on Monday, November 3rd. Guggenheim cut their price target on BioMarin Pharmaceutical from $106.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday. Canaccord Genuity Group upped their price target on shares of BioMarin Pharmaceutical from $98.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday. Wells Fargo & Company raised their price objective on shares of BioMarin Pharmaceutical from $70.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Finally, HC Wainwright dropped their target price on shares of BioMarin Pharmaceutical from $60.00 to $55.00 and set a “neutral” rating for the company in a research note on Wednesday. Fifteen equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $87.71.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in BMRN. CIBC Private Wealth Group LLC grew its position in shares of BioMarin Pharmaceutical by 38.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after buying an additional 179 shares during the period. Northwestern Mutual Investment Management Company LLC boosted its stake in BioMarin Pharmaceutical by 0.4% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock valued at $2,554,000 after acquiring an additional 183 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in BioMarin Pharmaceutical by 7.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,741 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 195 shares during the period. Sittner & Nelson LLC raised its position in shares of BioMarin Pharmaceutical by 6.9% during the 2nd quarter. Sittner & Nelson LLC now owns 3,100 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 200 shares during the last quarter. Finally, Grandfield & Dodd LLC raised its position in shares of BioMarin Pharmaceutical by 1.2% during the 3rd quarter. Grandfield & Dodd LLC now owns 18,967 shares of the biotechnology company’s stock valued at $1,027,000 after acquiring an additional 217 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.